Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer
- PMID:31378655
- DOI: 10.1016/j.clcc.2019.07.001
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer
Abstract
Introduction: Although neoadjuvant chemo-radiotherapy (CRT) achieves low local recurrence rates in locally advanced rectal cancer (LARC), it raises a lot of concerns about long-term anal and sexual functions. We explored the efficacy of preoperative chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) in patients with LARC.
Patients and methods: Patients with LARC evaluated by pelvic magnetic resonance imaging (MRI) were enrolled in this trial. All received 4 to 6 cycles of mFOLFOXIRI. MRI was performed to assess clinical response after chemotherapy. Patients with mesorectal fascia-positive or ycT4a/b after re-evaluation would receive radiation before surgery, whereas responders would have immediate total mesorectal excision (TME). Adjuvant chemotherapy with mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin) was recommended. The primary endpoint was the proportion of tumor downstaging to ypT0-2N0M0. The secondary endpoints were pathologic complete response rate (pCR), 3-year disease-free survival rate, and safety.
Results: Overall, 106 patients were enrolled and received neoadjuvant mFOLFOXIRI chemotherapy. A total of 103 participants underwent TME surgery. Among 103 patients who completed at least 4 cycles of preoperative chemotherapy, 2 received short-term radiation before TME, and 12 underwent long-term CRT after MRI evaluation. The pCR rate was 20.4%, and the tumor downstaging rate was 42.7%. Among patients without preoperative long-term radiotherapy, the pCR rate and tumor downstaging rate were 17.4% and 41.3%, respectively. Among the per-protocol population, the tumor downstaging rate was 48.1%, and the pCR rate was 20.3%. The chemotherapy-related toxicity was well-tolerated.
Conclusion: Neoadjuvant chemotherapy with mFOLFOXIRI and selective radiation does not seem to compromise outcomes in LARC. It could be a reasonable alternative to CRT in previously untreated patients with LARC.
Keywords: Avoid radiation; Preoperative; Triplet regimen; Tumor downstaging; pCR.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
- Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).Miwa K, Oki E, Enomoto M, Ihara K, Ando K, Fujita F, Tominaga M, Mori S, Nakayama G, Shimokawa M, Saeki H, Baba H, Mori M, Akagi Y.Miwa K, et al.BMC Cancer. 2021 Jan 5;21(1):23. doi: 10.1186/s12885-020-07766-5.BMC Cancer. 2021.PMID:33402130Free PMC article.Clinical Trial.
- Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.Zhang W, Zhou H, Jiang J, Zhu Y, Zou S, Jiang L, Tang Y, Liang J, Sun Y, Jiang Z, Qu W, Li Y, Zhou A.Zhang W, et al.BMC Cancer. 2023 Jun 27;23(1):592. doi: 10.1186/s12885-023-11103-x.BMC Cancer. 2023.PMID:37370032Free PMC article.Clinical Trial.
- Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB.Schrag D, et al.J Clin Oncol. 2014 Feb 20;32(6):513-8. doi: 10.1200/JCO.2013.51.7904. Epub 2014 Jan 13.J Clin Oncol. 2014.PMID:24419115Free PMC article.Clinical Trial.
- Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.Moretto R, Vetere G, Carullo M, Ciracì P, Masi G, Cremolini C.Moretto R, et al.Cancer Treat Rev. 2024 Nov;130:102829. doi: 10.1016/j.ctrv.2024.102829. Epub 2024 Sep 16.Cancer Treat Rev. 2024.PMID:39305700
- Neoadjuvant treatment intensification or adjuvant chemotherapy for locally advanced carcinoma rectum: The optimum treatment approach remains unresolved.Mallick S, Benson R, Haresh KP, Rath GK.Mallick S, et al.J Egypt Natl Canc Inst. 2015 Dec;27(4):179-85. doi: 10.1016/j.jnci.2015.05.003. Epub 2015 Jun 10.J Egypt Natl Canc Inst. 2015.PMID:26071798Review.
Cited by
- Efficacy Analysis of Combining Sintilimab with Neoadjuvant Chemotherapy in Treating Middle and Advanced Rectal Cancer Based on Big Data.Wang Y, Fei J, Zheng Y, Li P, Ren X, An Y.Wang Y, et al.J Oncol. 2022 Sep 16;2022:8675587. doi: 10.1155/2022/8675587. eCollection 2022.J Oncol. 2022.PMID:36157237Free PMC article.
- Predictive factors for early distant metastasis after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Park H.Park H.World J Gastrointest Oncol. 2021 Apr 15;13(4):252-264. doi: 10.4251/wjgo.v13.i4.252.World J Gastrointest Oncol. 2021.PMID:33889277Free PMC article.
- Neoadjuvant treatments for resectable rectal cancer: A network meta-analysis.Zhong W, Xue X, Dai L, Li R, Nie K, Zhou S.Zhong W, et al.Exp Ther Med. 2020 Apr;19(4):2604-2614. doi: 10.3892/etm.2020.8494. Epub 2020 Feb 5.Exp Ther Med. 2020.PMID:32256740Free PMC article.
- The "Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), Continuous Infusion 5-Fluorouracil, and Leucovorin for Colorectal Cancer".Deng Y; Chinese Southwest Oncology Group - the Committee of Colorectal Cancer.Deng Y, et al.Gastroenterol Rep (Oxf). 2021 Sep 23;9(4):279-289. doi: 10.1093/gastro/goab033. eCollection 2021 Aug.Gastroenterol Rep (Oxf). 2021.PMID:34567559Free PMC article.
- Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and stoma status in rectal cancer: long-term functional follow-up of a randomized clinical trial.He S, Zhang J, Wang R, Li L, Shi L, Ren D, Wang J, Deng Y, Dou R.He S, et al.BJS Open. 2022 Nov 2;6(6):zrac127. doi: 10.1093/bjsopen/zrac127.BJS Open. 2022.PMID:36321379Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials